Sassan Farjami, M.D., FACP

Business Address(es):

Office: Pacific Shores Medical Group

1043 Elm Avenue, Suite #104
Long Beach, CA 90813
Telephone: (562) 590-0345
Fax: (562) 983-0713

3747 Worsham Ave, Suite 101
Long Beach, CA 90808
Telephone: (562) 430-5900
Fax: (562) 799-8379

PERSONAL:

DATE OF BIRTH: June 25, 1968
MARITAL STATUS: Married, two children

EXPERENCE:

2006-PRESENT	Pacific Shores Medical Group Attending Physician, Hematology/Oncology

COLLEGE:

1983-1987	Shahriar College, Diploma in Mathematics and Physics Finished school as an honored student

MEDICAL SCHOOL:

1987-1994	Tehran University of Medical Sciences, Tehran, Iran Ranked among top 3% in final exam

POSTGRADUATE TRAINING:

2003-2006	Fellowship, Hematology/Oncology Westchester Medical Center University Hospital New York Medical College, Valhalla, New York
2002-2003	Fellowship, Geriatric Medicine Long Island Jewish Medical Center/Parker Jewish Geriatric Institute for Health Care and Rehabilitation Albert Einstein College of Medicine, New Hyde Park, New York
1999-2002	Internship/Residency, Internal Medicine The Mt Vernon Hospital/Westchester Medical Center University Hospital New York Medical College, Valhalla, New York

S.F
4/29/20

APPOINTMENTS:

2016- 2018	Chairman, Department of Medicine St. Mary Medical Center Long Beach, California.
2008-present	Teaching Head, Hematology, Internal Medicine Residency Program, St. Mary Medical Center, UCLA
2018-Present	Clinical Associate professor of Medicine, UCLA
2008-2018	Clinical Assistant Professor of Medicine, UCLA
2006-2008	Clinical Instructor of Medicine, UCLA
2003-2006	Chief Hematology/Oncology Fellow Westchester Medical Center, New York Medical College Valhalla, New York
2001-2002	Chief Medical Resident The Mt. Vernon Hospital, New York Medical College Mt. Vernon, New York
1996-1999	House Officer/ER Physician Iranmehr General Hospital Tehran, Iran
1994-1996	Director of Community Health Center Ilam University of Medical Sciences Ilam, Iran

BOARD CERTIFICATIONS:

2006	Diplomat, American Board of Hematology
2006	Diplomat, American Board of Oncology
2004	Diplomat, American Board of Geriatric Medicine
2003	Diplomat, American Board of Internal Medicine

HOSPITAL AFFILIATIONS:

St. Mary Medical Center, Long Beach, CA
Long Beach Memorial Medical Center, Long Beach, CA
Los Alamitos Medical Center, Los Alamitos, CA
Providence Little Company of Mary Medical Center, San Pedro, CA

PROFESSIONAL SOCIETY MEMBERSHIP:

2005	Member-Medical Society of State of New York

2003	Member-American Society of Hematology
2003	Member-American Society of Clinical Oncology
2002	Member-American Geriatric Society
1999	Member-American Medical Association
1999	Member-American Society of Internal Medicine

AWARDS:

2006	Travel Award NCCN Mar 2006
2005	Travel Award ASH Dec 2005
2004	Travel Award ASCO May 2004
2004	Travel Award ASH Dec 2004
2003	Recipient of Best Clinical Poster Award, Baltimore, MD
2000	Recipient of Best Intern Award, Mt Vernon Hospital, NY

PRESENTATIONS:

Advances in Biology and Treatment of Multiple Myeloma, Hematology/Oncology Ground Rounds; Westchester Medical Center, Valhalla, New York, November 2004

Epidermal Growth Factor Receptor Inhibitors: Mechanism and Rational as a Clinical Target, Hematology/Oncology Ground Rounds; Westchester Medical Center, Valhalla, New York, February 2004

An Update in Treatment of Prostate Cancer, Geriatric Medicine Ground Rounds; Long Island Jewish Medical Center, New Hyde Park, New York, April 2003

TTP associated with Metastatic Breast Cancer, Clinical Pathologic Conference; The Mt Vernon Hospital, Mt Vernon, New York, October 2001

Hepatitis C and Multiple Myeloma, Clinical Pathologic Conference; The Mt Vernon Hospital, Mt Vernon, New York, September 2000

Superior Vena Cava Syndrome associated with Anaplastic Thyroid Cancer, Clinical Pathologic Conference; The Mt Vernon Hospital, Mt Vernon, New York, June 2000

ABSTRACTS AND PUBLICATIONS:

Farjami S, Kancherla R, Hoang A, Puccio C, Mittleman A, Seiter K, Ahmed T. High Dose Chemotherapy with Autologous Stem Cell Rescue in Patients with Breast Cancer at High Risk for Relapse: Results of the Valhalla Experience with Dose- Intensive Therapy. Annual Meeting of the American Society of Clinical Oncology (ASCO) May 2005 Orlando, Florida.***Journal of Clinical Oncology Volume 23, Issue 16S June 1, 2005***

Farjami S, Akhtar A, Kancherla R, Liu D, Seiter K, Ahmed T. Progressively Intensified Chemotherapy: A Phase II Trial in Patients with Multiple Myeloma. Annual meeting of the American Hematology Association (ASH), Dec 2004 San Diego, California. ***Blood, Volume 104, issue 11, November 16, 2004***

Farjami, S, Nesheiwat O, Karmen C., Lerner R: An Unusual Case of Lead Poisoning *http://www.cyberounds.com October 2004*

Farjami S, Merchant A, Darvesh G, Acosta M, Wolf-Klein G, Silverstone F. Erythropoietin and Cognitive Function: A Case Report. Annual Meeting of the American Geriatrics Society (AGS) **Presidential Poster Presentation**, May 14-18, 2003. Baltimore, Maryland. ***Journal of American Geriatric Society; Volume 51 Issue s4 April 2003***

Farjami S, Aboudan M, Merchant A, Silverstone F, Wolf-Klein G. Beer Consumption, Folic Acid Intake and Vitamin B12 Deficiency in Elderly: A Case Report. Annual Meeting of the American Geriatrics

Society (AGS), May 14-18, 2003. Baltimore, Maryland. ***Journal of American Geriatric Society; Volume 51 Issue s4 April 2003***

Merchant A, Chowdhury Z, Shah U, Acosta M, **Farjami S**, Wolf-Klein G. Why Seek A Geriatrician? A Survey of Public Awareness and Needs. Annual Meeting of the American Geriatrics Society (AGS), May 14-18, 2003. Baltimore, Maryland. ***Journal of American Geriatric Society; Volume 51 Issue s4 April 2003***

Merchant A, Darvesh G, Wolf-Klein G, **Farjami S**, Cohen A. Acute Transverse Myelitis After Influenza Vaccination in a Patient with Multiple Sclerosis. Annual Meeting of the American Geriatrics Society (AGS), May 14-18, 2003. Baltimore, Maryland. ***Journal of American Geriatric Society; Volume 51 Issue s4 April 2003***

CLINICAL RESEARCH TRIALS (participated in as principal investigator or sub-investigator)

List of Protocols 2006 – February 2016

BREAST CANCER

- TORI AVF3694g: A Multicenter, Phase III, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy Regimens in subjects with Previously Untreated Metastatic Breast Cancer.
- NSABP B-41: A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.
- Wyeth 3144A1-2206-WW: A PHASE ½, OPEN-LABEL STUDY OF NERATINIB (HKI-272) IN COMBINATION WITH CAPECITABINE IN SUBJECTS WITH SOLID TUMORS AND ErbB-2 POSITIVE METASTATIC OR LOCALLY ADVANCED BREAST CANCER.
- TORI/NSABP BETH CIRG (TRIO) 011 / NSABP B-44-I / BO20906: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab.
- TORI/US Oncology 06-090: Phase III Trial of Adjuvant TC versus TAC in Early Stage HER-2-Negative Breast Cancer.
- TORI BIPAR 2009301: A phase 3, multi-center, open-label, randomized study of gemcitabine/carboplatin, with or without BSI-201, in patients with ER-, PR-, and HER2-negative metastatic breast cancer.
- Novartis CZOL446E2352: A prospective, randomized, double-blind, stratified, multi-center, 2-arm trial of the continued efficacy and safety of Zometa® (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from breast cancer.
- TORI/Pfizer: Phase I/II open-label, randomized study of the safety, efficacy, and pharmacokinetics of letrozole plus PD 0332991 (oral CDK 4/6 inhibitor) and letrozole single

agent for the first-line treatment of ER positive, HER2 negative advanced breast cancer in postmenopausal women.

- Sanofi 2010EAP: An Open-Label, Expanded Access Protocol of iniparib in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer.
- TORI D-CARE: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE).
- TRIO NSABP B-46-I: A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative Breast Cancer.
- GSK LPT112515: A Randomized, Phase III, Open-label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer.
- Amgen 20130100 CABS: Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer patients.
- BI 1200.75 (Lux Breast-1: LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2·overexpressing breast cancer failing one prior trastuzumab treatment.
- Bayer Bay 88-8223/16298 Xofigo: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy.
- Bayer Bay 88-8223/17096 Xofigo: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases.
- MONALEESA-3: A randomized double-blind, placebo controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment.

COLORECTAL CANCER

- AMGEN SPIRITT (Panitumumab) 20060141: A multi-center, open-label, randomized, phase 2 clinical trial evaluating safety and efficacy of FOLFIRI with either Panitumumab or Bevacizumab as second-line treatment in subjects with metastatic colorectal cancer.
- TORI CRAD001C2241: A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate), bevacizumab, fluoropyrimidine, oxaliplatin, and irinotecan-based regimens.

- Sanofi-Aventis VELOUR. EFC10262: A multinational, randomized, double-blind study, comparing the efficacy of AFIBERCEPT once every 2 weeks versus placebo in patients with metastatic colorectal cancer (MCRC) treated with irinotecan/5-FU combination (FOLFIRI) after failure of an oxaliplatin based regimen.

- Enzon Pharmaceuticals: EZN-2208-04: A Phase 2 Study of EZN-2208 (PEG-SN38) Administered with or without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC).

- TORI: A Phase III Randomized Double-Blind Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer.

- TORI/Pfizer B2151005: A Randomized Phase 2 study of PF-05212384 plus Irinotecan versus Cetuximab plus irinotecan in patients with KRAS Wild type metastatic colorectal cancer.

- TORI/Pfizer B2151007: An Open-label, multi-center, randomized phase 1B/2 study of PF-05212384 plus 5-Fluorouracil-leucovorin-irinotecan (FOLFIRI) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer.

- Gilead GS-US-295-0203: A phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-6624 Combined with FOLFIRI as second line treatment for metastatic KRAS or BRAF mutant colorectal adenocarcinoma that has progressed following a first line Oxaliplatin and Fluoropyrimidine-containing regimen.

HEAD AND NECK

- TORI GI-05: A phase II study of Erlotinib and modified FOLFOX-6 (5-fluorouracil, Leucovorin and Oxaliplatin) in previously untreated patients with unresectable or metastatic adenocarcinoma of the esophagus and gastric cardia.

- Lilly 14E-MC-JXBD: A randomized, double-blind, phase 2 safety study of Cetuximab, using ImClone versus Boehringer Ingelheim manufacturing processes, in combination with cisplatin or carboplatin and 5-Fluorouraci in the first-line treatment of patients with locoregionally recurrent and/or metastatic squamous cell carcinoma of the head and neck.

- AstraZeneca D4193C00001 HAWK: A phase II, multi-center, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

- AstraZeneca D4193c0003 CONDOR: A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.

HEMATOLOGIC CANCER

- Gilead GS-US-339-0103 A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination with Idelalisib in Subjects with Relapsed or Refractory Hematologic Malignancies.

HEPATOCELLULAR CARCINOMA

- Amgen 20080580: Phase 2, open-label, single-arm, multi-center study to evaluate the efficacy and safety of AMG 386 and sorafenib as first line therapy for subjects with advanced of inoperable hepatocellular carcinoma.

LEUKEMIA

- Gilead GS-US-312-0123 An open-label, multicenter Phase 1b/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.

- Tori: 152c1201: A randomized, open-label, multicenter, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide, and rituximab versus fluarabine, cyclophosphamide, and rituximab alone in subjects with relapsed chronic lymphocytic leukemia.

LUNG CANCER

- TORI H3E-MC-JMHD(b): Randomized, open-label, phase 3 study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small cell lung cancer.

- TORI D4200C00032 A Phase III, Randomized, Double-Blinded, Multi-Center Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERET™) in combination with Placebo in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapy.

- Abraxis CA031: A randomized, phase III trial of ABI-007 and carboplatin compared with taxol and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.

- Boehringer Ingelheim 1199.14: Multi-center, randomized, double-blind, phase III trial to investigate the efficacy and safety or oral BiBF 120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent non-small cell lung cancer after failure of first line chemotherapy.

- AMGEN 20120249: A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Denosumab in Combination with Chemotherapy as First-line Treatment of Metastatic Non-Small Cell Lung Cancer

- TORI/NCI L-03: A randomized, open-label phase II clinical trial of combination Erlotinib (Tarceva) and Fulvestrant (Faslodex) versus Erlotinib (Tarceva) alone in advanced or metastatic non-small cell lung cancer patients.

- TORI/Lilly 14T-MC-JVBA(a): A randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy.

- Merck Serono EMR 63325-021: A multicenter, randomized, double-blind, placebo controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC).

- Genentech GO28758: A randomized, phase III, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of onartuzumab in combination with erlotinib as first-line treatment for patients with met-positive unresectable stage IIIB or IV non–small cell lung cancer (nsclc) carrying an activating EGFR mutation.

- Boehringer Ingelheim LUX-Lung EAP: An open label expanded access program of afatinib (BIBW 2992) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s).

- TRIO/Genentech G028915 OAK: A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (anti-PD-L1 Antibody) compared with docetaxel in patients with non-small cell lung cancer after failure with platinum-containing chemotherapy.

- Novartis cCLDK378A2112: A phase I, multi-center, randomized open label study to assess the systemic exposure and safety of 450 mg Ceritinib taken with a low-fat meal and 600 mg certininib taken with a low-fat meal as compared with that of 750 mg Ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer.

- AstraZeneca D419AC0003 NEPTUNE: A phase III randomized, open-label, multi-center, global study of MED14736 in combination with Tremelimumab therapy versus standard of care platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic non-small cell lung cancer.

LYMPHOMA

- CALISTOGA PHARMACEUTICALS INC: A phase 2 study to assess the efficacy and safety of CAL 101 in patients with indolent B-cell non-Hodgkin's lymphoma refractory to rituximab and alkylating agents.

- Cell Therapeutics PIX306: A randomized multicenter study comparing pixantrone + rituximab with gemcitabine + rituximab in patients with aggressive b-cell non-Hodgkin's lymphoma who have relapsed after therapy with CHOP-R or an equivalent regimen and are ineligible for stem cell transplant.

- TORI 26866138-LYM-3001: A randomized, open label, multi-center study of Velcade with Rituximab or Rituximab Alone in Subjects with relapsed or refractory, rituximab naïve or sensitive follicular B-cell non-Hodgkin's lymphoma.

- Amgen 531: An open-label dose and schedule finding trial to evaluate the safety and efficacy of AMG 531 for treatment of severe thrombocytopenia due to multi-cycle chemotherapy in adult subjects with lymphoma.

- Gilead GS-US-313-0124: A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas.

- Gilead GS-US-313-0125: A phase e, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib (DS-1001) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas.

- TRIO/ICON C25003: A phase e randomized, two-arm trial of Brentuximab vedontin plus AVD versus ABVD as front-line therapy in patients with advanced classical Hodgkin lymphoma.

- Pfizer 05280586: A phase 3, randomized, double-blind study of PF-05280586 versus rituximab for the first-line treatment of patients with CD20 positive, low tumor burden, follicular lymphoma.

- Gilead GS-US 313-1580: Dose optimization study of Idelalisib in follicular lymphoma or small lymphocytic lymphoma.

MELANOMA

- Bristol Myers Squibb CA184-045: A multicenter treatment protocol for compassionate use of ipilimumab (BMS-734016) monotherapy in subjects with unresectable stage III or stage IV melanoma.

- Bristol Myers Squibb CA184-143: A multi-site, prospective, observational study in US patients with advanced melanoma.

- Lilly H8K-MD-JZAO: A randomized phase 3 study of tasisulam administered as an intravenous infusion on day 1 of a 28-day cycle versus paclitaxel as second-line treatment in patients with metastatic melanoma.

MULTIPLE MYELOMA

- Proteolix PX-171-006: Phase 1B multi-center dose escalation study of carfilzomib with Lenalidomide and dexamethasone for safety and activity in relapsed multiple myeloma.

- Kyowa Kirin: An open-label, dose escalation, multicenter phase ½ study of KW2478 in combination with bortezomib in subjects with relapsed and/or refractory multiple myeloma.

- BMS CA204006: A phase 3, randomized, open label trial of Lenalidomide/dexamethasone with or without Elotuzumab in subjects with previously untreated multiple myeloma.

PANCREATIC CANCER

- TORI/Amgen 20060323: A Phase 1b/2 study to evaluate the safety and efficacy of AMG655 or AMG 479 in combination with gemcitabine as first-line therapy for metastatic pancreatic cancer.

- Abraxis CA046: A randomized phase III study of weekly ABI-007 plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas.

- Gilead GS-US-324-0101: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma.

- TRIO-TORI/NCI PA-01: A multicenter, open-label, randomized, phase II trial of adjuvant dasatinib plus gemcitabine versus single-agent gemcitabine in patients with resected pancreatic adenocarcinoma.

- Incyte INCB 18424-362 Janus 1: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With

Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study).

- TRIO/Oncomed 59R5-002 Alpine: A Phase 1b/2 Study of OMP-59R5 in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Previously Untreated Stage IV Pancreatic Cancer.
- Celgene ABI-007-PANC-CA046C MPCT Extension study: Multicenter, survival data collection in subjects previously enrolled in protocol CA046.
- IMMU-107-04: An international, multi-center, double-blind, randomized, phase III trial of 90Y-clivatuzumab Tetraxetan plus low-dose gemcitabine versus placebo plus low-dose gemcitabine in patients with metastatic Stage IV pancreatic adenocarcinoma who received at least two prior treatments.

PROSTATE CANCER

- UCLA ROLL GUP 0205-1X: An Open-Label 48-Month Extension Study of the Effects of Pomegranate Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy For Prostate Cancer
- Sanofi-Aventis EFC6193 (TROPIC): A randomized, open label multi-center study of XRP6258 at 25 mg/m2 in combination with prednisone every 3 weeks compared to mitoxantrone in combination with prednisone for the treatment of hormone refractory metastatic prostate cancer previously treated with a taxotere-containing regimen.
- UCLA ROLL GUP 0205-1xx: A 48-month extension to the randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising prostate-specific antigen levels in men following primary therapy for prostate cancer.
- Amgen 20080537: An open label, single arm, extension study to evaluate the long-term safety of denosumab (AMG162) in the treatment of bone loss in subjects undergoing androgen-deprivation therapy for non-metastatic prostate cancer.
- Novartis: A randomized multi-center phase II trial of patupilone (EP0906) plus prednisone versus docetaxel (Taxotere) plus prednisone in patients with metastatic hormone-refractory prostate cancer.
- Dendreon P10-3: A registry of Sipuleucel-T therapy in men with advanced prostate cancer.
- Bayer Xofigo REASSURE: Observational study for the evaluation of long-term safety of radium-223 used for the treatment of metastatic castration resistant prostate cancer.

RENAL CANCER

- Eisai E7080-G000-205: An open-label, multicenter Phase 1b/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.

SOLID TUMORS

- Amgen CA225315: A study to evaluate the relationship between Cetuximab therapy and corrected QT (QTc) interval changes in patients with advanced malignancies from solid tumors.

- Amgen 20050130: An Open Label Treatment Extension Study of AMG 706

SYMPTOM CONTROL

- Heron Therapeutics Protocol APPA C2013-01: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Subjects Receiving Highly Emetogenic Chemotherapy.

03/25/2016